This result strongly suggests lack of cross-resistance between EV and ETx-22 and confirmed the biological relevance of nectin-4 as a tumor-targeting antigen, in particular for patients whose cancer has progressed on EV therapy. The gene discussed is NECTIN4; the disease is neoplasm.